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6. SUMMARY
Muscle relaxation is an important coÍnerstone of
anesthesia. Muscle relaxation simpliÍ ies endotracheal
intubation, improves operating conditions and may
improve ventilating conditions in intensive care
patients. Muscle relaxation is obtained mainly by the
administration of speciÍic drugs, the so-called muscle
relaxants and for a small part by the administration oÍ
less speciÍic drugs such as propoÍol, benzodiazepines
and inhalational anesthetics. Muscle relaxants can be
divided into two groups according to the mode of
action: dÍugs which act by blocking receptors, without
p r e c e d i n g  s t i m u l a t i o n  o f  t h e  r e c e p t o r s
{nondepolarizing) and drugs which act by blocking
Íeceptors with preceding stimulation oÍ the receptors
(depotarizing),
Muscle relaxants were introduced into clinical
anesthesia in 1942, ln that year GriÍÍ ith and Johnson
from Montreal published an article, in which the use oÍ
curare in spontaneously breathing patients was
reported. By doing this deep inhalational anesthesia
producing circulatory and respiratory depression could
be circumvented. lt was thought that the abdominal
muscles could be relaxed, thereby improving operating
conditions, without depressing the respiratory muscles,
since at that t ime assisted or artif icial venti lation was
not a routine. Besides this technique, used in the USA
and Canada, a technique oÍ complete muscle relaxation
including artiÍ icial venti lation was developed in
England. The latteÍ technique is considered today to be
the state of the art { 'balanced anesthesia'}.
The problem associated with relaxation of abdominal ,
muscles in spontaneously breathing patients was the
development of respiratory insufÍiciency. ln the case of
insufficient recognition and treatment oÍ this, hypoxia
and hypercarbia may develop resulting in serious
complications. lt must be remembered that monitoring
of circulation and respiration was very l imited in those
days (no electrocardiogram, no pulse oximetry, no
capnography). Also, very oÍten postoperative
monitoring and treatment in recovery Íooms were
absent, The probtem oÍ hypoventilation was quantiÍ ied
in a very large American study oÍ Beecher and Todd, in
which the use oÍ muscle relaxation in 599548 patients
'increased mortality six fold. Sixtythree percent oÍ these
" muscle relaxant deaths" were due to respiratory
complications and 37 percent were due to circulatory
complications. However, crit ics oÍ this study stated
that the "muscle relaxant deaths" related to respiratory
insuÍf iciency were probably due to inadequate
recognition and tÍeatment oÍ unwanted efÍects of
muscle relaxants and thus due to inappropriatie use of
muscle relaxants.
Nevertheless, it is possible that, when appropriately
used, the administration of currently available muscle
relaxants may lead to mortality and morbidity, due to
the slow Íate oÍ onset and the slow recovery of
neuromuscular block, to cardiovascular effecets and to
the effects of immunological and nonimmunological
histamine release. The use oÍ depolarizing muscle
relaxants may. by induction oÍ cardiac arrest and
malignant hyperthermia, also lead to mortality and
morbidity. In the opinion oÍ investigators and the
pharmaceutical industry it is therefore necessary to
develop muscle relaxants with an improved
pharmacological proÍi le. According to them, there is a
need Íor a muscle relaxant with a Íast rate oÍ onset
and short duration oÍ action with minimal unwanted
eÍfects, in Íact a nondepolarizing substitute for the
depolar iz ing succiny lchol ine.  Research In the 1 980's
and 1990's revealed that  th is  muscle re laxant  might  be
Íound within the series of low potency muscle
relaxants i.e., muscle relaxants with a low aÍÍinity Íor
the receptors in the neuromuscular junction. In
contrast, clinicians often state that the repertory oÍ
currently available muscle relaxants does not need
expansion, since in their opinion the currently available
muscle relaxants do not signiÍicantly contÍibute to
anesthetic mortality and morbidity.
PerÍorming phase l, l l  and l l l  cl inical trials with low
potency muscle re laxants in  the1990's a iming at
Íurther improvement of the pharmacological profi le of
muscle relaxants, one could ask oneselÍ three
quest ions:  (1)  does the anesthesio logical  wor ld real ly
need better muscle relaxants and iÍ so (21 what can be
learned Írom the existing l iterature with respect to the
development oÍ "better" muscle relaxants to date and
(3) is it the right direction oÍ the curÍent clinical re-
search to focus on low potency muscle relaxants?. The
aim of this thesis is to try to Íind anwers to these three
questions.
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(l I Does the anesthesiological world really need
"better" muscle relaxants.
This question implies an evaluation oÍ the
anesthesiological iterature concentrated on the risk
related to the use oÍ currently available muscle
relaxants. ThereÍore epidemiological and caset studies
were reviewed in chapter 2, to assess the muscle
relaxant-induced mortality and morbidity related to the
rate of onset and rate of oÍÍset of neuromuscular
block, cardiovascular eÍfects, effects of immunological
and nonimmunological histamine release and related to
other phenomena, in particular those induced by
depolarizing musclê relaxants. This l iterature search
revealed that the use oÍ cuÍrently available muscle
relaxants is associated with serious and important
complications, even iÍ the muscle relaxants were
proper ly  used.  ln  general .  the c l in ica l ly  avai lable
nondepolarizing muscle relaxants induce and terminate
their neuromuscular blocking action too slowly, and/or
induce unwanted cardiovascular efÍects and histamine
release. Succinylcholine, the only clinically available
muscle relaxant with the desirable time course oÍ
act ion i .e . ,  a  Íast  rate oÍ  onset  (<1 minute)  and shor t
duration of action (5-10 minutes), induces serious
complications such as caÍdiac arrest and malignant
hyperthermia. The latter complications are related to its
depolarizing mode oÍ action. The exact incidence oÍ
the complications related to the use oÍ muscle
relaxants remains unclear mainly as a result of
insuÍÍicient methodology oÍ the reviewed studies, but
seems to be low. However, at least theoretically,
anesthetic outcome could be improved iÍ better muscle
relaxants, in particular a nondepolarizing substitute Íor
the depolar iz ing agent  succiny lchol ine,  became
available. Thus, the anesthesiological world needs a
betteÍ muscle relaxànt and this is the justiÍ ication Íor
the Íurther search Íor muscle relaxants with an
improved pharmacological  proÍ i le .
(2) What can be learned from the existing literature
with respect to the development of better muscle
relaxants to date?
To answer this question, all cl inically used muscle
relaxants were l isted in chapter 3. Their pharma-
cological proÍi les were screened with respect to
general features related to the occurÍence oÍ unwanted
eÍÍects. Unwanted eÍÍects include an insufficiently fast
rate of onset and an insufÍiciently Íast rate of oÍfset oÍ
the neuromuscular block, cardiovascular eÍf ects,
eÍÍects oÍ immunological and nonimmunological
histamine release and other eÍÍects, in particular those
induced by depolarizing muscle relaxants. This review
has revealed to date that two types oÍ nondepolarizing
muscle relaxants i.e., steroidal and benzyliso-
quinolinium derivatives, have a more favourable
pharmacological proÍi le than other types. In the clinical
dose range, steroidal muscle relaxants may induce
tachycardia mediated by vagal block, but do not induce
vasodilation mediated by ganglion block oí efÍects
mediated by nonimmunological histamine release. The
oÍÍset oÍ steroidal-induced neuromuscular block is
dependent on redistribution and renal and liver
c learance.  Newer benzyl isoquinol in ium muscle
relaxants, in the clinical dose range, lack tachycardia
mediated by vagal block as well as vasodilation
mediated by ganglion block, but may induce eÍÍects
mediated by nonimmunological histamine release. Due
to a reverse ester l inkage, the oÍÍset oÍ neurómuscular
block of atracurium and cisatracurium is mainly
dependen t  on  Ho fmann  deg rada t i on  i . e . ,  a
spontaneous pH-dependent degradation, while that oÍ
mivacurium is mainly dependent on enzymatic
breakdown by pseudocholinesterase. This implies
relatíve independence on oÍgan Íunction in the case oÍ
atracurium and cisatracurium. In the case of
mivacurium, neuromuscular block wil l be prolonged
when pseudocholinesterase activity is diminished. Both
steroidal and benzylisoquinolinium muscle relaxants
may induce eÍÍects mediated by immunological
histamine release.
A general feature oÍ steroidal as well as oÍ
benzylisoquinolinium uscle relaxants is that a lower
Íeceptor aÍÍinity leads to a Íaster rate oÍ onset oÍ
neuromuscular block. This means that when a muscle
relaxant has a relatively low receptor aÍfinity i.e., a low
intrinsic potency, a relatively large number oÍ
molecules has to be administered to obtain a certain
degree of neuromuscular block. The ED* value is thus
relatively high. However, the Íate of onset oÍ
neuromuscular block is only one aspect oÍ the
pharmacological proÍi le of muscle relaxants. What
other consequences has low potency on the
pharmacological proÍi le i.e., the offset of neuro-
muscular block, cardiovascular eÍÍects and eÍíects
mediated by histamine release? Will the ideal muscle
relaxant be a low potency muscle relaxant? This leads
to question three.
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í3) ls it the right direction of the current clinical re-
search to focus on low potency muscle relaxants?
This question is answered in chapter 4. By reviewing
theoretical considerations, mechanisms afÍecting the
rate oÍ onset and oÍfset of neuromuscular block,
mechanisms aÍÍecting the incidence and magnitude of
cardiovascular eÍÍects, and mechanisms aÍfecting the
incidence and magnitude of nonimmunological and
immunological histamine release were investigated.
These mechanisms were then related to the
pharmacological prof i le oÍ low potency muscle re-
laxants and predictions were made with respect to the
induction oÍ unwanted eÍÍects by low potency muscle
relaxants.
It was concluded that low potency, although the
key to a Íast rate oí onset of neuromuscular block
induced by nondepolarizing muscle relaxants, does not
result in a short duration oÍ action unless the low
potency is based on pronounced init ial plasma
clearance. High init ial plasma clearance can be
obtained either by rapid redistribution or by rapid
degradation i  plasma or in tissue, or by a combination
oÍ  these two mechanisms.  Recovery Í rom
neuromuscular block by redistribution is a typical
Íeature of steroidal muscle relaxants whereas recovery
oÍ neuromuscular block by degradation is a typical
Íeature of benzylisoquinolinium muscle relaxants.
Furthermore, in the case oÍ steroidal muscle relaxants,
low potency increases the l ikelihood vasodilatation
mediated by calcium channel block, and in the case oÍ
benzylisoquinolinium muscle relaxants, of eÍÍects
mediated by nonimmunological histamine release. Thus
there seems to be a l imit to the benificial eÍÍect oí low
potency oÍ muscle relaxant when a safe pharma-
cological proÍi le is persued. In terms of ED*.nu in
gmolikg these limits are probably in the range oÍ 2
/moilkg (oED*nu of Org 9487 and Org 9453) íor
steroidal muscle relaxants and in the range oÍ 0.2
pmol/kg (o EDso.es oÍ atracurium) Íor benzyl-
isoquinolinium uscle relaxants. At these EDeo.e5 the
íate of onset of neuromuscular block is Íast Íollowing a
steroidal muscle relaxant and slow Íollowing a
benzylisoquinolinium uscle relaxants. The advantage
oí benzylisoquinolinium muscle relaxants is their
degradation in plasma which is Íast in the case of
mivacurium, leading to a relatively Íast rate oÍ ofÍset oÍ
neuromuscular block.
More improvement can probably be obtained by
combining the best oÍ Íeatures of steroidal and
benzylisoquinolinium muscle relaxants. Theoretically,
an ideal muscle relaxant would be obtained by
synthesing oÍ a low potency steroidal muscle relaxant
with a biodegradable l inkage between the two nitrogen
groups.
The studies presented in the supplements oÍ this thesis
supply data with respect to the pharmacological
proÍi les oÍ relatively low potency steroidal muscle
relaxants. These studies are phase l, l l  and l lt cl inical
trials and supply data useÍul Íor the reviews oÍ chapteÍ
3 and 4. These studies do not supply safety data. For
this purpose many thousands of adminístratíons in
postmarketing surveil lance studies over several years
are required.
Supplement 1 reveals data of Org 9273, a muscle
relaxant with an EDno of 3OO /g/kg. This muscle
relaxant induces a neuromuscular block characterized
by a Íast onset (t 1 min) oÍ good to excellent
intubating conditions aÍteÍ its administration and an
intermediate duration of action (a train-of-Íour ratio of
0.7 is obtained aÍter t 60 min), a neuromuscular
proÍi le similaÍ to that oÍ ÍocuÍonium (see supplements 2
and 3). At doses oÍ 3-4 times the ED* Org 9273
produces an increase in heart rate oÍ approximately 20-
25"/", probably as a result of vagolysis, without
signiÍicant changes in systolic or diastolic arterial blood
pressure. Due to the cardiovascular efÍects, although
only prominent after 3-4 times the ED* dose, Org
9273 was not evaluated further since its t ime couíse
was not different Írom that oÍ rocuronium. The latter,
however, does not produce clinically appaÍent
cardiovascular effects in the clinical dose range.
Supplement 2 demonstrates that rocuronium, a muscle
relaxant with an EDno oÍ 300 /S/kS, produces a
neuromuscular block with a fast onset (t ' l  min) oÍ
good to excellent intubating conditions aÍter its
administÍation, with an intermediate duration of action
(a train-oÍ-four ratio oÍ 0.7 is obtained after t 60 minl,
and with prompt reversibil i ty aï 75o/o neuromuscular
block. The rocuronium-induced neuromuscular block is
inÍluenced by volati le anesthetics in a similar way to
that of other muscle relaxants. Evaluation oÍ the
pharmacokinetic profi le of rocuronium revealed that
12-220/" oí the administered dose is excreted by the
kidney within 24 hours and that the pharmacokinetics
are not inÍluenced by the anesthetic technique.
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The study presented in supplement 3 was perÍormed
to evaluate the early reversibil i ty of the neuromuscular
block induced by rocuronium. lt was hypothesized
that a deep neuromuscular block induced by muscle
re laxant  wi th a low potency,  which usual ly  a lso impl ies
a low receptor aff inity, may be more eÍÍectively
reversed than that induced by a more potent muscle
relaxant. In that case, rocuronium would have an
increased saÍety proÍi le with respect to oÍÍset oÍ
neuromuscular block. However, the results reveal that
early reversal oÍ a rocuronium-induced neuromuscular
b lock by neost igmine i .e . ,  2  min aÍ ter  adminis t rat ion of
an intubating dose of rocuronium, does not have any
advantage over reversal at 25o/o recovery. The
decreased potency oÍ the muscle relaxant is not
associated wi th improved revers ib i l ty  by neost igmine,
since results are similar to those obtained with
vecuronium, a more potent  muscle re laxant .  Moreover,
the rate and magnitude oÍ neostigmine-induced
recovery wil l be goveÍned by the pharmacokinetics of
both rocuronium and neostigmine.
The studies presented in supplements 2 and 3
shows  tha t  t he  impor tan t  improvemen t  i n
pharmacological  prof  i le  oÍ  rocuronium over  other
c l in ica l ly  avai lable nondepolar iz ing muscle re laxants is
its Íast onset oÍ neuromuscular block and early good to
excellent intubating conditions. This may lead to a
decrease in the number of pulmonary and ventilatory
complications during the induction of anesthesia.
Supplement 4 presents data with respect to another
low potency muscle relaxant, Org 9487. lts EDoo is
1 .15  mg /kg .  I n  a  dose  o Í  1 .5  mg /kg ,  Org  9487  i nduces
a neuromuscular block which is characterized by a fast
onset  ( t  1  min)  oÍ  good to excel lent  in tubat ing
conditions and a relatively short duration oÍ action (a
train-of-four ratio of 0.7 is obtained after t 25 minl.
This relatively short duration of action may have
advantages in the case oÍ short surgical procedures.
Also, due to the Íast spontaneous recovery of a ' l  .5
mg/kg Org 9487-induced neuromuscular block, the
neuromuscular block can already be reversed 2
minutes after the administration of Org 9487, leading
to a rapid ÍecoveÍy. This feature may improve saÍety in
the case oÍ failed intubation. lt is concluded that the
use of Org 9487 may improve saÍety both during onset
and oÍÍset oÍ neuromuscular block.
Supplement 5 reveals data from an inÍusion study oí
Org 9487. The results demonstrate that a desirable
Surgical degree oÍ neuromuscular block i.e., 75-85%
block is easily maintained by an infusion of Org 9487.
However, aÍteí only one hour oÍ inÍusion, the recovery
oÍ neuromuscular block of Org 9487 was prolonged
(see supplement 4), similar to the observations with
vecuronium. The results presented in supplements 4
and 5 demonstrate that Org 9487 in particular
thereÍore more in particulaÍ suitable Íor endotracheal
intubation and for shortlasting interventions ((30
min l .
Supplement 6 supports the contention that it is
Íeasible to develop shortacting nondepolarizing muscle
re laxan ts  w i t h i n  t he  s te ro ida l  se r i es .  The
neuromuscular block induced by the very low potency
Org 7617 (its EDno is t 3.4 mg/kgl is characterized by
a fast onset and ultra short duration of action. This
neuromuscular blocking proÍi le is similar to that oÍ
succinylcholine. However, clinical investigations were
terminated prematurely due to dose dependent
caÍdiovascular effects, and serious side eÍÍects
suggestive oÍ histamine release.
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